Vitamin D for a better response to chemotherapy
Treatments studied
Part of Cancer, Hormones & metabolism, Skin clinical trials.
This study tests whether taking high-dose vitamin D before and during chemotherapy helps eliminate more cancer before surgery in people with triple-negative breast cancer who are low in vitamin D.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with invasive breast cancer that is triple-negative (meaning the cancer lacks three common receptors).
- You are planning to receive chemotherapy before surgery.
- You have not had surgery, radiation, or chemotherapy for this breast cancer yet.
- You are at least 18 years old.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This study tests a combination of chemotherapy and immunotherapy given before surgery for triple-negative breast cancer. It aims to shrink the tumor and improve outcomes. The treatment is given intravenously.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests whether adding dasatinib and quercetin to your treatment can reverse resistance to chemotherapy in triple negative breast cancer that has spread or come back. It aims to help your body respond better to treatment.
This trial uses special imaging before and after treatment to see if it can predict how well triple-negative breast cancer responds to chemotherapy plus immunotherapy given before surgery. Participation could help doctors tailor future treatments.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.